Dopamine modulates risk-taking as a function of baseline sensation-seeking trait.
Trait sensation-seeking, defined as a need for varied, complex, and intense sensations, represents a relatively underexplored hedonic drive in human behavioral neuroscience research. It is related to increased risk for a range of behaviors including substance use, gambling, and risky sexual practice. Individual differences in self-reported sensation-seeking have been linked to brain dopamine function, particularly at D2-like receptors, but so far no causal evidence exists for a role of dopamine in sensation-seeking behavior in humans. Here, we investigated the effects of the selective D2/D3 agonist cabergoline on performance of a probabilistic risky choice task in healthy humans using a sensitive within-subject, placebo-controlled design. Cabergoline significantly influenced the way participants combined different explicit signals regarding probability and loss when choosing between response options associated with uncertain outcomes. Importantly, these effects were strongly dependent on baseline sensation-seeking score. Overall, cabergoline increased sensitivity of choice to information about probability of winning; while decreasing discrimination according to magnitude of potential losses associated with different options. The largest effects of the drug were observed in participants with lower sensation-seeking scores. These findings provide evidence that risk-taking behavior in humans can be directly manipulated by a dopaminergic drug, but that the effectiveness of such a manipulation depends on baseline differences in sensation-seeking trait. This emphasizes the importance of considering individual differences when investigating manipulation of risky decision-making, and may have relevance for the development of pharmacotherapies for disorders involving excessive risk-taking in humans, such as pathological gambling.
Institute of Cognitive Neuroscience, University College London, London WC1N 3AR, United Kingdom. agnes.norbury.10@ud.ac.uk
Agnes
A
Norbury
Sanjay
S
Manohar
Robert D
RD
Rogers
Masud
M
Husain
D000328:Adult; D000704:Analysis of Variance; D000077465:Cabergoline; D002755:Choice Behavior / Q000187:drug effects / Q000502:physiology*; D003657:Decision Making / Q000187:drug effects / Q000502:physiology*; D004294:Domperidone / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D004311:Double-Blind Method; D004873:Ergolines / Q000494:pharmacology; D005260:Female; D005717:Games, Experimental; D006801:Humans; D007206:Individuality; D008570:Memory, Short-Term / Q000187:drug effects / Q000502:physiology*; D011336:Probability; D012309:Risk-Taking; D057566:Self Report; D012677:Sensation / Q000187:drug effects / Q000502:physiology*; D055815:Young Adult
D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D004873:Ergolines; D004294:Domperidone; D000077465:Cabergoline; D004298:Dopamine